Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 31;69(1):e0098824.
doi: 10.1128/aac.00988-24. Epub 2024 Nov 21.

Olorofim demonstrates in vitro activity against Coccidioides species, including isolates against which fluconazole has reduced activity

Nathan P Wiederhold  1   2 , Hoja P Patterson  1 , Dora Ferrer  1 , Victor Garcia  1 , George R Thompson  3 , Thomas F Patterson  2
Affiliations

Olorofim demonstrates in vitro activity against Coccidioides species, including isolates against which fluconazole has reduced activity

Nathan P Wiederhold et al. Antimicrob Agents Chemother. .

Abstract

We evaluated the in vitro activity of olorofim against Coccidioides species. Olorofim demonstrated potent in vitro activity against all isolates tested with a minimum inhibitory concentration (MIC) range ≤0.008-0.06 µg/mL and geometric mean MIC of 0.010 µg/mL. This activity was also maintained against isolates with elevated fluconazole MICs (≥16 µg/mL), including strains with MICs ≥32 µg/mL (olorofim MIC range ≤0.008-0.06 µg/mL and geometric mean MICs of ≤0.009 and ≤0.013 µg/mL, respectively).

Keywords: Coccidioides species; fluconazole; in vitro susceptibility; olorofim.

PubMed Disclaimer

Conflict of interest statement

This study and olorofim powder were provided by F2G, Ltd. N.P.W. has received research support to the UT Health San Antonio from bioMerieux, F2G, Mycovia, Sfunga, and Scynexis and has served on an advisory board for F2G. G.R.T. has served as a consultant and received research support from Astellas, Amplyx, Cidara, F2G, Mayne, Melinta, Mundipharma, Scynexis, and the DSMB for Pfizer. T.F.P. has served as a consultant and/or received research support from Cidara, F2G, Gilead, Scynexis, and Elion Therapeutics.

Figures

Fig 1
Fig 1
MIC distributions of olorofim, amphotericin B, fluconazole, posaconazole, voriconazole, itraconazole, and isavuconazole against Coccidioides species isolates. Results are shown for all isolates tested and those with higher fluconazole MIC values (≥16 µg/mL and ≥32 µg/mL, respectively).
See this image and copyright information in PMC

References

    1. Talamantes J, Behseta S, Zender CS. 2007. Statistical modeling of valley fever data in Kern County, California. Int J Biometeorol 51:307–313. doi:10.1007/s00484-006-0065-4 - DOI - PubMed
    1. Stevens DA. 1995. Coccidioidomycosis. N Engl J Med 332:1077–1082. doi:10.1056/NEJM199504203321607 - DOI - PubMed
    1. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, Williams PL, Infectious Diseases Society of America . 2005. Coccidioidomycosis. Clin Infect Dis 41:1217–1223. doi:10.1086/496991 - DOI - PubMed
    1. Ashraf N, Kubat RC, Poplin V, Adenis AA, Denning DW, Wright L, McCotter O, Schwartz IS, Jackson BR, Chiller T, Bahr NC. 2020. Re-drawing the maps for endemic mycoses. Mycopathologia 185:843–865. doi:10.1007/s11046-020-00431-2 - DOI - PMC - PubMed
    1. Gorris ME, Treseder KK, Zender CS, Randerson JT. 2019. Expansion of coccidioidomycosis endemic regions in the United States in response to climate change. Geohealth 3:308–327. doi:10.1029/2019GH000209 - DOI - PMC - PubMed

Publication types

MeSH terms

Grants and funding